Prognostic Value of Volume-Based Metabolic Parameters Measured by 18F-FDG PET/CT of Pancreatic Neuroendocrine Tumors

被引：31

作者：

Kim H.S. ^{[1
]}

Choi J.Y. ^{[1
]}

Choi D.W. ^{[2
]}

Lim H.Y. ^{[3
]}

Lee J.H. ^{[1
]}

Hong S.P. ^{[1
]}

Cho Y.S. ^{[1
]}

Lee K.-H. ^{[1
]}

Kim B.-T. ^{[1
]}

机构：

[1] Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, 50 Irwon-dong, Gangnam-gu

[2] Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, 50 Irwon-dong, Gangnam-gu

[3] Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, 50 Irwon-dong, Gangnam-gu

来源：

Nuclear Medicine and Molecular Imaging | 2014年 / 48卷 / 3期

关键词：

Metabolic tumor volume; Pancreatic neuroendocrine tumor; Prognosis; Total lesion glycolysis;

D O I：

10.1007/s13139-013-0262-0

中图分类号：

学科分类号：

摘要：

Purpose: To date, the prognostic value of 18F-FDG PET/CT for patients with pancreatic neuroendocrine tumors (PNETs) has not been well characterized. We investigated the prognostic value of volumetric parameters using 18F-FDG PET/CT in this patient population. Methods: We retrospectively reviewed 20 cases of pathologically proven PNET in patients who had undergone pre-therapeutic 18F-FDG PET/CT. PET parameters including maximum and average standardized uptake values (SUVmax, SUVave), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor were measured using a threshold SUV to determine the boundaries of the tumors. Univariate and multivariate survival analyses were performed with adjustments for PET parameters and other clinical values. Results: The median clinical follow-up was 22.3 (range, 1.2-95.4) months. Cancer-related death occurred in 5 of 20 patients (25 %). Patients had clinical or pathological stages of I in seven patients, II in six patients, III in three patient, and IV in four patients. According to the WHO histological classification of subtypes, 3 patients exhibited well-differentiated PNETs, 13 patients had well-differentiated endocrine carcinomas, and 4 had poorly differentiatedendocrine carcinomas. Univariate analysis showed that tumor size (p = 0.028), AJCC stage (p = 0.009), T stage (p = 0.028), M stage (p = 0.029), treatment modality (p = 0.045), MTV (p = 0.003) and TLG (p = 0.027) were significant predictors of overall survival. On multivariate analysis, MTV (HR = 10.859, p = 0.031) was a significant independent predictor of overall survival along with the AJCC stage (HR = 11.556, p = 0.027). Conclusion: In patients with PNETs, the MTV of the primary tumor as measured by 18F-FDG PET/CT along with the AJCC stage may be a significant independent prognostic factor for overall survival. © 2014 Korean Society of Nuclear Medicine.

引用

页码：180 / 186

页数：6

共 30 条

[21]

Krenning E.P., Bakker W.H., Breeman W.A., Koper J.W., Kooij P.P., Ausema L., Et al., Localization of endocrine-related tumours with radioiodinated analogue of somatostatin, Lancet, 1, pp. 242-244, (1989)

[22]

Maldonado A., Gonzalez-Alenda F.J., Alonso M., Sierra J.M., PET-CT in clinical oncology, Clin Transl Oncol, 9, pp. 494-505, (2007)

[23]

Minn H., Lapela M., Klemi P.J., Grenman R., Leskinen S., Lindholm P., Et al., Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer, J Nucl Med, 38, pp. 1907-1911, (1997)

[24]

Allal A.S., Slosman D.O., Kebdani T., Allaoua M., Lehmann W., Dulguerov P., Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-d-glucose, Int J Radiat Oncol Biol Phys, 59, pp. 1295-1300, (2004)

[25]

Soret M., Bacharach S.L., Buvat I., Partial-volume effect in PET tumor imaging, J Nucl Med, 48, pp. 932-945, (2007)

[26]

Hatt M., Visvikis D., Pradier O., Cheze-Le R.C., Baseline -FDG PET image-derived parameters for therapy response prediction in oesophageal cancer, Eur J Nucl Med Mol Imaging, 38, pp. 1595-1606, (2011)

[27]

Lee S.J., Choi J.Y., Lee H.J., Baek C.H., Son Y.I., Hyun S.H., Et al., Prognostic value of volume-based 18F-fluorodeoxyglucose PET/CT prameters in patients with clinically node-negative oral tongue squamous cell carcinoma, Korean J Radiol, 13, pp. 752-759, (2012)

[28]

Arslan N., Miller T.R., Dehdashti F., Battafarano R.J., Siegel B.A., Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer, Mol Imaging Biol, 4, pp. 301-310, (2002)

[29]

Lairmore T.C., Piersall L.D., DeBenedetti M.K., Dilley W.G., Mutch M.G., Whelan A.J., Et al., Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1), Ann Surg, 239, pp. 637-645, (2004)

[30]

Blansfield J.A., Choyke L., Morita S.Y., Choyke P.L., Pingpank J.F., Alexander H.R., Et al., Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs), Surgery, 142, pp. 814-818, (2007)

← 1 2 3 →